<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2703210644
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Duserex
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DUTASTERIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, soft
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        81.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OLIVE HEALTHCARE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OLIVE HEALTHCARE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04CB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>The active ingredient is Dutasteride. It belongs to a group of medicines called 5-alpha reductase inhibitors.</p><p><strong>Duserex capsule is used to treat men with an enlarged prostate</strong> (benign prostatic hyperplasia) -a noncancerous growth of the prostate gland, caused by producing too much of a hormone called dihydrotestosterone.</p><p>As the prostate grows, it can lead to urinary problems, such as difficulty in passing urine and a need to go to the toilet frequently. It can also cause the flow of the urine to be slower and less forceful. If left untreated, there is a risk that your urine flow will be completely blocked (acute urinary retention). This requires immediate medical treatment. In some situations, surgery is necessary to remove or reduce the size of the prostate gland. Duserex capsule lowers the production of dihydrotestosterone, which helps to shrink the prostate and relieve the symptoms. This will reduce the risk of acute urinary retention and the need for surgery.</p><p>Duserex capsules may also be used with another medicine called tamsulosin (used to treat the</p><p>symptoms of an enlarged prostate)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Duserex capsules</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you&rsquo;re allergic to Dutasteride, other 5-alpha reductase inhibitors, soya, peanut or to any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe liver disease.</p><p>If you think any of these apply to you, don&rsquo;t take this medicine until you have checked with your doctor.</p><p><strong>This medicine is for men only</strong>. It must not be taken by women, children or adolescents.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Duserex capsules:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Make sure your doctor knows about liver problems</strong>. If you have had any illness affecting your liver, you may need some additional check-ups while you are taking Duserex capsules.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Women, children and adolescents</strong> must not handle leaking Duserex capsules, because the active ingredient can be absorbed through the skin. <strong>Wash the affected area immediately</strong> with soap and water if there is any contact with the skin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Use a condom during sexual intercourse.</strong> Duserex has been found in the semen of men taking Duserex capsules. If your partner is or may be pregnant, you must avoid exposing her to your semen as Duserex may affect the normal development of a male baby. Duserex has been shown to decrease sperm count, semen volume and sperm motility. This could reduce your fertility.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Duserex capsules affects a blood test for PSA</strong> (prostate-specific antigen), which is sometimes used to detect prostate cancer. Your doctor should be aware of this effect and can still use the test to detect prostate cancer. If you are having a blood test for PSA, tell your doctor that you are taking Duserex capsules. <strong>Men taking Duserex capsules should have their PSA tested regularly.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In a clinical study of men at increased risk of prostate cancer, men taking Duserex capsules <strong>had a serious form of prostate cancer</strong> <strong>more often</strong> than men who did not take Duserex capsules. The effect of Duserex capsules on this serious form of prostate cancer is not clear.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Duserex capsules may cause breast enlargement and tenderness</strong>. If this becomes troublesome, or if you notice breast lumps or nipple discharge you should talk to your doctor about these changes as these may be signs of a serious condition, such as breast cancer.</p><p><strong>Contact your doctor or pharmacist </strong>if you have any questions about taking Duserex capsules.</p><p>&nbsp;</p><p><strong>Other medicines and Duserex capsules</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>Some medicines can react with Duserex capsules and may make it more likely that you&rsquo;ll have side-effects.</p><p>These medicines include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil or diltiazem (for high blood pressure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir or indinavir (for HIV)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itraconazole or ketaconazole (for fungal infections)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nefazodone (an antidepressant)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alpha-blockers (for enlarged prostate or high blood pressure).</p><p><strong>Tell your doctor</strong> if you are taking any of these medicines. Your dose of Duserex capsules may need</p><p>to be reduced.</p><p><strong>Duserex capsules with food and drink</strong></p><p>Duserex capsules can be taken with or without food.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>Women who are pregnant (or may be) must not handle leaking capsules. Duserex is absorbed through</p><p>the skin and can affect the normal development of a male baby. This is a particular risk in the first 16 weeks of pregnancy.</p><p><u>Use a condom during sexual intercourse</u>. Duserex has been found in the semen of men taking</p><p>Duserex capsules. If your partner is or may be pregnant, you must avoid exposing her to your semen.</p><p>Duserex capsules has been shown to reduce sperm count, semen volume and sperm movement.</p><p>Therefore male fertility may be reduced.</p><p><strong>Contact your doctor</strong> for advice if a pregnant woman has come into contact with Duserex.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Duserex capsule is unlikely to affect your ability to drive or operate machinery.</p><p><strong>Duserex capsules contains lecithin from soya</strong></p><p>This medicine contains lecithin from soya, which may contain soya oil. If you are allergic to peanut or soya,do not use this medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor or pharmacist has told you to</strong>.If you do not take it</p><p>regularly the monitoring of your PSA levels may be affected. Check with your doctor or pharmacist if you are not sure.</p><p><strong>How much to take</strong></p><p>- <strong>The recommended dose is one capsule (0.5 mg) taken once a day.</strong> Swallow the capsules whole with</p><p>water. Do not chew or break open the capsule.</p><p>- Duserex capsule is a long term treatment. Some men notice an early improvement in their symptoms.</p><p>However, others may need to take Duserex capsules for 6 months or more before it begins to have an</p><p>effect. Keep taking Duserex capsules for as long as your doctor tells you.</p><p>&nbsp;</p><p><strong>If you take more Duserex capsules than you should</strong></p><p>Contact your doctor or pharmacist for advice if you take too many Duserex capsules.</p><p><strong>If you forget to take Duserex capsules</strong></p><p>Do not take a double dose to make up for a forgotten dose. Just take your next dose at the usual time.</p><p><strong>Don&rsquo;t stop taking Duserex capsules without advice</strong></p><p>Don&rsquo;t stop taking Duserex capsules without talking to your doctor first. It may take up to 6 months or</p><p>more for you to notice an effect.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Like all medicines, this medicine can cause side effects, although not everybody gets them.</strong></p><p><strong>Allergic</strong> <strong>reaction</strong></p><p>The signs of allergic reactions can include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash (which can be itchy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (like a nettle rash)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the eyelids, face, lips, arms or legs.</p><p><strong>Contact you doctor immediately</strong> if you get any of these symptoms, <strong>and stop using Duserex capsules</strong>.</p><p><strong>Common side effects</strong></p><p><em>These may affect up to 1 in 10 men taking Duserex Accord:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not able to achieve or maintain an erection (impotence) *this may continue after you stop taking Duserex</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased sex drive (libido) this may continue after you stop taking Duserex capsules</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty with ejaculation this may continue after you stop taking Duserex capsules</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast enlargement or tenderness (gynecomastia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness when taken with tamsulosin</p><p><strong>Uncommon side effects</strong></p><p><em>These may affect up to 1 in 100 men taking Duserex Accord:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure (heart becomes less efficient at pumping blood around the body. You may have symptoms such as shortness of breath, extreme tiredness and swelling in your ankles and legs)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -hair loss (usually from the body) or hair growth</p><p><strong>Not known side effects</strong></p><p><em>The frequency cannot be estimated from the available data:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depressed mood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain and swelling in your testicles</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Store in the original container to protect from moisture.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw</p><p>away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Dutasteride.</p><p>Each soft capsule contains 0.5 mg Dutasteride.</p><p>The other ingredients are:</p><p>-inside the capsule: glycerol monocaprylocaprate (type I), butylhydroxytoluene (E321).</p><p>-capsule shell: gelatine, glycerol, titanium dioxide (E171), ferric oxide yellow (E172</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Soft gelatin capsule
Dull yellow Opaque color, oblong shape soft gelatin capsule containing clear transparent liquid imprinted with “DUTA05” using black color ink.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer by:</strong></p><p>OLIVE Healthcare - India for MS Pharma-Saudi.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sep-19
SPM190545

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة: دوتاستيريد ينتمي هذا الدواء إلى مجموعة من الأدوية تُسمّى بالأدوية المثبطة للإنزيم المُختزل 5 ألفا.</p><p dir="RTL">يستخدم دواء ديوسيركس في علاج الرجال الذين يعانون من تضخم البروستاتا (فرط نسيج البروستاتا الحميد)، وهو عبارة عن نمو غير سرطاني لغدة البروستاتا بسبب الإفراز المُفرط لهرمون ثنائي هيدروتيستوستيرون.</p><p dir="RTL">مع نمو البروستاتا، يمكن أن يؤدي ذلك إلى مشاكل في المسالك البولية، مثل صعوبة في التبول والحاجة إلى الذهاب إلى المرحاض بشكل متكرر. كما قد يتسبب في أن يكون تدفق البول أبطأ وأقل قوة. إذا ترك ذلك دون علاج، فهناك خطر في أن يصاب المريض باحتباس تام في تدفق البول (احتباس حاد في البول). حيث أن ذلك يتطلب التلقي الفوري للعلاج. في بعض الحالات، تكون الجراحة ضرورية لإزالة أو تقليل حجم غدة البروستاتا. يعمل دواء ديوسيركس على التقليل من إنتاج هرمون ثنائي هيدروتيستوستيرون مما يساعد في تقليص حجم البروستاتا والتخفيف من حدة الأعراض. سوف يقلل ذلك من خطر الإصابة باحتباس البول الحاد والحاجة لإجراء الجراحة.</p><p dir="RTL">قد يستخدم دواء ديوسيركس مع دواء آخر يسمى تامسولوسين (يستخدم في علاج أعراض تضخم البروستاتا).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول دواء ديوسيركس في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; إذا كانت لديك حساسية مفرطة لمادة دوتاستيريد أو لأحد الأدوية المثبطة للإنزيم المُختزل 5 ألفا أو الصويا أو الفُستق/ الفول السوداني أو لأي مكونات أخرى في هذا الدواء (من المكونات المذكورة في الفقرة 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض شديد في الكبد.</p><p dir="RTL">إذا كنت تعتقد بأن أي من ذلك ينطبق عليك، فلا تتناول هذا الدواء إلا بعد مراجعة الطبيب.</p><p dir="RTL">يستخدم هذا الدواء للرجال فقط. يُحذر تناول النساء أو الأطفال أو المراهقين لهذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">استشر الطبيب قبل تناول هذا الدواء:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>احرص على التأكد من أن الطبيب على اطلاع بمشاكل الكبد التي تعاني منها.</strong> إذا كنت قد عانيت من أي مرض يؤثر على الكبد، فقد تحتاج لإجراء بعض الفحوصات الاضافية أثناء علاجك بهذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على النساء والأطفال والمراهقين عدم لمس كبسولات ديوسيركس لاحتمالية حدوث تسرّب منها، وذلك لأنه المادة الفعالة يمكن أن تُمتص عبر الجلد. يجب غسل الجزء المصاب فورا باستخدام الصابون والماء إذا حدث أي تلامس عبر الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>استخدم الواقي الذكري أثناء العلاقة الحميمة.</strong> تم العثور على ديوسيركس في السائل المنوي للرجال الذين يتناولون هذا الدواء. إذا كانت زوجتك حاملا أو يحتمل أن تكون حاملا، فيجب عليك تجنب تعرضها للسائل المنوي لأنه قد يؤثر على النمو الطبيعي للجنين الذكر. وجدنا أن دواء ديوسيركس يتسبب في تقليل عدد الحيوانات المنوية وحجم السائل المنوي وحركة الحيوانات المنوية. حيث أن ذلك قد يقلل من الخصوبة.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>يؤثر دواء ديوسيركس على اختبار فحص مستضد البروستاتة النوعي (PSA)، والذي قد يستخدم أحيانا في الكشف عن سرطان البروستاتا. ينبغي أن يكون الطبيب على علم بهذا التأثير، ولا يزال بإمكانه استخدام هذا الاختبار للكشف عن سرطان البروستاتا. إذا كنت ستخضع لإجراء اختبار فحص مستضد البروستاتة النوعي PSA))، فيجب أن تخبر الطبيب بأنك تتناول هذا الدواء.<strong> يجب أن يقوم الرجال الذين يتناولون دواء ديوسيركس بإجراء&nbsp; فحص مستضد البروستاتة النوعي (</strong><strong>PSA</strong><strong>) بصورة منتظمة.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في دراسة سريرية أجريت على الرجال المعرضين لخطر الإصابة بسرطان البروستاتا، كان لدى الرجال الذين يتناولون دواء ديوسيركس نوع أخطر من سرطان البروستاتا بنسبة أكبر من الرجال الذين لم يتناولوا دواء ديوسيركس. من غير الواضح تأثير دواء ديوسيركس على هذا النوع الخطير من سرطان البروستاتا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قد يتسبب دواء ديوسيركس في تضخم الثدي وإيلامه.</strong> إذا أصبح هذا الأمر مزعجًا، أو إذا لاحظت وجود كتل في الثدي أو إفرازات من حلمة الثدي، فيجب عليك التحدث مع الطبيب حول هذه التغييرات لأن ذلك قد يكون علامات على الإصابة بحالة خطيرة ، مثل سرطان الثدي.</p><p dir="RTL">استشر الطبيب أو الصيدلي إذا كان لديك أي سؤال حول تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى مع دواء ديوسيركس </strong></p><p dir="RTL">يجب إخبار الطبيب إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر.</p><p dir="RTL">يمكن أن تتفاعل بعض الأدوية مع دواء ديوسيركس مما قد يجعلك أكثر عرضة للإصابة بالأعراض الجانبية.</p><p dir="RTL">وهذه الأدوية تشمل الآتي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل أو ديلتيازيم (تستخدم في علاج ارتفاع ضغط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير أو إندينافير (يستخدم في علاج مرض الإيدز / فيروس نقص المناعة البشري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيتراكونازول أو كيتاكونازول (يستخدم في علاج العدوى الفطرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفازودون (يستخدم في علاج الاكتئاب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات المستقبلات الأدرينالية ألفا (تستخدم في علاج تضخم البروستاتا أو ارتفاع ضغط الدم)</p><p dir="RTL">أخبر الطبيب إذا كنت تتناول أي من هذه الأدوية. قد يحتاج الطبيب لإنقاص الجرعة التي تتناولها من دواء ديوسيركس.</p><p dir="RTL">.</p><p dir="RTL"><strong>تناول كبسولات ديوسيركس مع الطعام والمشروبات</strong></p><p dir="RTL">يمكن تناول هذا الدواء مع الطعام أو بدونه.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">يحذر على السيدات الحوامل (أو اللاتي يحتمل حملهن) تناول / لمس الكبسولات .&nbsp;&nbsp; يُمتص ديوسيركس من خلال الجلد، وقد يؤثر على التطور الطبيعي للجنين الذكر.</p><p dir="RTL">. يشكل ذلك خطرا خاصة في أول 16أسبوع من الحمل.</p><p dir="RTL">استخدم الواقي الذكري أثناء العلاقة الحميمة. تم العثور على ديوسيركس في السائل المنوي للرجال الذين يتناولون هذا الدواء.</p><p dir="RTL">. إذا كانت زوجتك حاملا أو يحتمل أن تكون حاملا، فيجب عليك تجنب تعريضها للسائل المنوي.</p><p dir="RTL">وجدنا أن دواء ديوسيركس يتسبب في تقليل عدد الحيوانات المنوية وحجم السائل المنوي وحركة الحيوانات المنوية.</p><p dir="RTL">ومن ثم فإنه قد يؤثر على خصوبة الذكر.</p><p dir="RTL">استشر الطبيب إذا وصل هذا الدواء لأي أنثى في أثناء حملها.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يؤثر ديوسيركس على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>يحتوي دواء ديوسيركس على الليسيثين المشتق من الصويا.</strong></p><p dir="RTL">يحتوي هذا الدواء على الليسيثين المشتق من الصويا، والذي قد يحتوي على زيت الصويا.&nbsp; إذا كان لديك حساسية للصويا أو الفستق&nbsp; / الفول السوداني، فلا تستخدم هذا الدواء.</p><p dir="RTL">.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تناول هذا الدواء وفقًا لتعليمات الطبيب أو الصيدلي.</p><p dir="RTL">قد تتأثر مستويات مستضد البروستاتة النوعي (PSA) إذا لم تتناول هذا الدواء بانتظام.&nbsp; يرجى التوجه بالسؤال للطبيب أو الصيدلي في حالة عدم تأكدك.</p><p dir="RTL"><strong>الجرعة التي يجب تناولها من الدواء</strong></p><p dir="RTL">الجرعة المُوصى بها هي كبسولة واحدة (0.5 ملغم) في اليوم. قم ببلع الكبسولة بأكملها باستخدام الماء.</p><p dir="RTL">. لا تقم بمضغ أو تفتيت الكبسولات.</p><p dir="RTL">.</p><p dir="RTL">دواء ديوسيركس هو علاج طويل الأمد. يلاحظ بعض الرجال تحسن مبكر في أعراضهم.</p><p dir="RTL">ومع ذلك؛ فقد يتطلب الأمر من بعض الحالات تناول الدواء لمدة 6 أشهر أو أكثر حتى تظهر فاعليته.</p><p dir="RTL">. استمر في تناول الدواء طالما أن الطبيب يخبرك بذلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تناولت جرعات من دواء ديوسيركس أكثر من الموصى بها</strong></p><p dir="RTL">استشر الطبيب أو الصيدلي من أجل طلب النصيحة إذا تناولت جرعات زائدة من دواء ديوسيركس.</p><p dir="RTL"><strong>إذا نسيت تناول الدواء</strong></p><p dir="RTL">لا تتناول جرعة مزدوجة لتعويض جرعتك الفائته. عليك فقط تناول الجرعة التالية في وقتها المعتاد.</p><p dir="RTL"><strong>لا تتوقف عن تناول الدواء دون استشارة الطبيب.</strong></p><p dir="RTL">لا تتوقف عن تناول الدواء دون التحدث إلى الطبيب حول ذلك أولا.&nbsp; قد يتطلب الأمر 6 أشهر أو أكثر كي تلاحظ تأثير الدواء.</p><p dir="RTL"><strong>يرجى استشارة الطبيب أو الصيدلي إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء.</strong></p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى.</strong></p><p dir="RTL">رد الفعل التحسسي</p><p dir="RTL">قد تشمل علامات رد الفعل التحسسي الأعراض الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي (والذي قد يكون به حكة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شري (يشبه طفح القراص الجلدي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في جفن العين أو في الوجه أو الشفاه أو الذراعين أو الساقين.</p><p>&nbsp;</p><p dir="RTL">استشر الطبيب على الفور إذا عانيت من أي من هذه الأعراض، وتوقف عن تناول الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية المألوفة</strong></p><p dir="RTL"><em>قد تؤثر هذه الأعراض في 1 من بين 10 رجال يتناولون هذا الدواء:</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على الوصول إلى الانتصاب أو الحفاظ عليه (الضعف الجنسي) * قد يستمر هذا التأثير بعد التوقف عن تناول الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الدافع الجنسي (الرغبة الجنسية)، وقد يستمر ذلك أيضا بعد التوقف عن تناول الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في القذف، وقد يستمر ذلك أيضا بعد التوقف عن تناول الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي أو إيلام في الثدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار إذا ما تم تناوله مع دواء تامسولوسين</p><p dir="RTL"><strong>الأعراض الجانبية غير المألوفة</strong></p><p dir="RTL"><em>قد تؤثر هذه الأعراض في 1 من بين 100 رجل يتناولون هذا الدواء:</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور القلب (يصبح القلب أقل كفاءة في ضخ الدم إلى الأجزاء المختلفة من الجسم). قد تعاني من بعض الأعراض مثل قصر النفس، الشعور الشديد بالتعب، تورم في الكاحلين والقدمين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر (عادة من شعر الجسم) أو نمو الشعر</p><p dir="RTL"><strong>الأعراض الجانبية التي لا يُعلم نسب تكررها</strong></p><p dir="RTL"><em>الأعراض الجانبية التي لا يمكن تحديد نسبة تكرارها من البيانات المتاحة:</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزاج مكتئب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وتورم في الخصيتين</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على شريط الأقراص وعلى العبوة بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">يجب عدم تخزينها في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">يحفظ الدواء في عبوته الأصلية من أجل الحفاظ عليه من الرطوبة.</p><p dir="RTL">لا تقم بإلقاء أية أدوية في مياه الصرف أو في النفايات المنزلية. وبدلاً عن ذلك قم باستشارة الصيدلي عن كيفية التخلص الآمن</p><p dir="RTL">من الأدوية التي لم تعد في حاجة إليها. ستساعد هذه الإجراءات في المحافظة على البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة: دوتاستيريد</p><p dir="RTL">تحتوي كل كبسولة على 0.5 ملغم من مادة دوتاستيريد.</p><p dir="RTL">باقي المكونات:</p><p dir="RTL">المحتويات الموجودة داخل الكبسولة: الجلسرين أحادي الكبريتات (النوع الأول)، الهيدروكسي طولوين المبيتل (مضاد للتأكسد) (E321).</p><p dir="RTL">المحتويات الموجودة في الغلاف: جلاتين، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديد الأصفر (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كبسولة جلاتينية طريّة .</p><p dir="RTL">لون الكبسولة أصفر غامق ، جلاتينية طرية ، مستطيلة الشكل وتحتوي على سائل شفاف واضح، مطبوع عليها &quot;DUTA05&quot; باستخدام حبر أسود اللون.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية</p><p dir="RTL">الرياض ، المملكة العربية السعودية .</p><p dir="RTL">&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:&nbsp; </strong><strong>&nbsp;</strong></p><p dir="RTL">اوليف للرعاية الصحية - الهند <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Sep-19
SPM190545

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Duserex 0.5 mg soft Gelatin capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each soft gelatin capsule contains
Dutasteride Ph Eur 0.5 mg
Excipients q.s.
For a full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Soft Gelatin Capsule.
Dull yellow Opaque color, oblong shape soft gelatin capsule containing clear transparent liquid imprinted with “DUTA05” using black color ink. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH).</p><p>Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH. For information on effects of treatment and patient populations studied in clinical trials please see section 5.1.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>Dutasteride capsules can be administered alone or in combination with the alpha-blocker tamsulosin (0.4mg) (see sections 4.4, 4.8 and 5.1).</p><p><em>Adults (including elderly):</em></p><p>The recommended dose of Dutasteride capsule is one capsule (0.5 mg) taken orally once a day. Although an improvement may be observed at an early stage, it can take up to 6 months before a response to the treatment can be achieved. No dose adjustment is necessary in the elderly.</p><p><em>Renal impairment</em></p><p>The effect of renal impairment on dutasteride pharmacokinetics has not been studied. No adjustment in dosage is anticipated for patients with renal impairment (see section 5.2).</p><p><em>Hepatic impairment</em></p><p>The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied so caution should be used in patients with mild to moderate hepatic impairment (see section 4.4 and section 5.2). In patients with severe hepatic impairment, the use of dutasteride is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>The capsules should be swallowed whole and not chewed or opend as contact with the capsule contents may result in irritation of the oropharyngeal mucosa. The capsules may be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dutasteride capsule is contraindicated in:
- women and children and adolescents (see section 4.6).
- patients with hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, soya, peanut or any of the other excipients listed in section 6.1.
- patients with severe hepatic impairment.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Combination therapy should be prescribed after careful benefit risk assessment due to the potential increased risk of adverse events (including cardiac failure) and after consideration of alternative treatment options including monotherapies (see section 4.2).</p><p><em>Cardiovascular adverse events</em></p><p>In two 4-year clinical studies, the incidence of cardiac failure (a composite term of reported events, primarily cardiac failure and congestive cardiac failure) was higher among subjects taking the combination of dutasteride and an alpha blocker, primarily tamsulosin, than it was among subjects not taking the combination. However, the incidence of cardiac failure in these trials was lower in all actively treated groups compared to the placebo group, and other data available for dutasteride or alpha-blockers do not support a conclusion on increased cardiovascular risks (see section 5.1).</p><p><em>Prostate cancer and high grade tumours</em></p><p>The REDUCE study, a 4-year, multicentre, randomised, double-blind, placebo controlled study investigated the effect of dutasteride 0.5 mg daily on patients with a high risk for prostate cancer (including men 50 to 75 years of age with PSA levels of 2.5 to 10 ng/ml and a negative prostate biopsy 6 months before study enrolment) compared to placebo. Results of this study revealed a higher incidence of Gleason 8 &ndash; 10 prostate cancers in dutasteride treated men (n=29, 0.9%) compared to placebo (n=19, 0.6%). The relationship between dutasteride and Gleason 8 - 10 prostate cancers is not clear. Thus, men taking Dutasteride capsules should be regularly evaluated for prostate cancer (see section 5.1).</p><p><em>Prostate specific antigen (PSA)</em></p><p>Serum prostate-specific antigen (PSA) concentration is an important component in the detection of prostate cancer. Dutasteride causes a decrease in mean.serum PSA levels by approximately 50%, after 6 months of treatment.</p><p>Patients receiving dutasteride should have a new PSA baseline established after 6 months of treatment with Dutaseride capsules. It is recommended to monitor PSA values regularly thereafter. Any confirmed increase from lowest PSA level while on Dutasteride capsules may signal the presence of prostate cancer or noncompliance to therapy with Dutasteride capsules and should be carefully evaluated, even if those values are still within the normal range for men not taking a 5-alpha-reductase inhibitor (see section 5.1). In the interpretation of a PSA value for a patient taking Dutasteride capsules, previous PSA values should be sought for comparison.</p><p>Treatment with Dutasteride capsules does not interfere with the use of PSA as a tool to assist in the diagnosis of prostate cancer after a new baseline has been established.</p><p>Total serum PSA levels return to baseline within 6 months of discontinuing treatment. The ratio of free to total PSA remains constant even under the influence of Dutasteride. If clinicians elect to use percent free PSA as an aid in the detection of prostate cancer in men undergoing Dutasteride capsules therapy, no adjustment to its value appears necessary.</p><p>Digital rectal examination, as well as other evaluations for prostate cancer, must be performed on patients prior to initiating therapy with Dutasteride capsules and periodically thereafter.</p><p><em>Leaking capsules:</em></p><p>Dutasteride is absorbed through the skin, therefore, women, children and adolescents must avoid contact with leaking capsules (see section 4.6). If contact is made with leaking capsules, the contact area should be washed immediately with soap and water.</p><p><em>Hepatic impairment:</em></p><p>Dutasteride was not studied in patients with liver disease. Caution should be used in the administration of dutasteride to patients with mild to moderate hepatic impairment (see section 4.2, section 4.3 and section 5.2).</p><p><em>Breast neoplasia</em></p><p>There have been rare reports of male breast cancer reported in men taking dutasteride in clinical trials and during the post- marketing period. However, epidemiological studies showed no increase in the risk of developing male breast cancer with the use of 5-alpha reductase inhibitors (see section 5.1). Physicians should instruct their patients to promptly report any changes in their breast tissue such as lumps or nipple discharge.</p><p>This medicinal product contains lecithin derived from soya oil. If you are allergic to peanut or soya, do not use this medicinal product (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For information on the decrease of serum PSA levels during treatment with dutasteride and guidance concerning prostate cancer detection, please see section 4.4.</p><p><em>Effects of other drugs on the pharmacokinetics of dutasteride</em></p><p><em>Use together with CYP3A4 and/or P-glycoprotein-inhibitors:</em></p><p>Dutasteride is mainly eliminated via metabolism.&nbsp;<em>In vitro</em>&nbsp;studies indicate that this metabolism is catalysed by CYP3A4 and CYP3A5. No formal interaction studies have been performed with potent CYP3A4 inhibitors. However, in a population pharmacokinetic study, dutasteride serum concentrations were on average 1.6 to 1.8 times greater, respectively, in a small number of patients treated concurrently with verapamil or diltiazem (moderate inhibitors of CYP3A4 and inhibitors of P-glycoprotein) than in other patients.</p><p>Long-term combination of dutasteride with drugs that are potent inhibitors of the enzyme CYP3A4 (e.g. ritonavir, indinavir, nefazodone, itraconazole, ketoconazole administered orally) may increase serum concentrations of dutasteride. Further inhibition of 5-alpha reductase at increased dutasteride exposure, is not likely. However, a reduction of the dutasteride dosing frequency can be considered if side effects are noted. It should be noted that in the case of enzyme inhibition, the long half-life may be further prolonged and it can take more than 6 months of concurrent therapy before a new steady state is reached.</p><p>Administration of 12 g colestyramine one hour after a 5 mg single dose of dutasteride did not affect the pharmacokinetics of dutasteride.</p><p><em>Effects of dutasteride on the pharmacokinetics of other drugs</em></p><p>Dutasteride has no effect on the pharmacokinetics of warfarin or digoxin. This indicates that dutasteride does not inhibit/induce CYP2C9 or the transporter P-glycoprotein.&nbsp;<em>In vitro</em>&nbsp;interaction studies indicate that dutasteride does not inhibit the enzymes CYP1A2, CYP2D6, CYP2C9, CYP2C19 or CYP3A4.</p><p>In a small study (N=24) of two weeks duration in healthy men, dutasteride (0.5 mg daily) had no effect on the pharmacokinetics of tamsulosin or terazosin. There was also no indication of a pharmacodynamic interaction in this study</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dutasteride capsule is contraindicated for use by women.</p><p><em>Fertility</em></p><p>Dutasteride has been reported to affect semen characteristics (reduction in sperm count, semen volume, and sperm motility) in healthy men (see section 5.1). The possibility of reduced male fertility cannot be excluded.</p><p><em>Pregnancy</em></p><p>As with other 5 alpha reductase inhibitors, dutasteride inhibits the conversion of testosterone to dihydrotestosterone and may, if administered to a woman carrying a male foetus, inhibit the development of the external genitalia of the foetus (see section 4.4). Small amounts of dutasteride have been recovered from the semen in subjects receiving dutasteride 0.5 mg a day. It is not known whether a male foetus may be adversely affected if his mother is exposed to the semen of a patient being treated with dutasteride (the risk of which is greatest during the first 16 weeks of pregnancy).</p><p>As with all 5 alpha reductase inhibitors, when the patient&#39;s partner is or may potentially be pregnant it is recommended that the patient avoids exposure of his partner to semen by use of a condom.</p><p>For information on preclinical data, see section 5.3</p><p><em>Breast-feeding</em></p><p>It is not known whether dutasteride is excreted in human milk.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on the pharmacodynamic properties of dutasteride, treatment with dutasteride would not be expected to interfere with the ability to drive or operate machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>DUTASTERIDE 0.5 CAPSUAS MONOTHERAPY</p><p>Approximately 19% of the 2167 patients who received dutasteride in the 2 year Phase III placebo-controlled trials developed adverse reactions during the first year of treatment. The majority of events were mild to moderate and occurred in the reproductive system. No change to the adverse event profile was apparent over a further 2 years in open-label extension studies.</p><p>The following table shows adverse reactions from controlled clinical trials and post-marketing experience. The listed adverse events from clinical trials are investigator-judged drug-related events (with incidence more than or equal to 1%) reported with a higher incidence in patients treated with dutasteride compared with placebo during the first year of treatment. Adverse events from post-marketing experience were identified from spontaneous post-marketing reports; therefore the true incidence is not known:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to, &lt;1/1,000); Very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Organ system</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Incidence from clinical trial data</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Incidence during year 1 of treatment (n=2167)</strong></p></td><td style="vertical-align:top"><p><strong>Incidence during year 2 of treatment (n=1744)</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Impotence*</p></td><td style="vertical-align:top"><p>6.0%</p></td><td style="vertical-align:top"><p>1.7%</p></td></tr><tr><td style="vertical-align:top"><p>Altered (decreased) libido*</p></td><td style="vertical-align:top"><p>3.7%</p></td><td style="vertical-align:top"><p>0.6%</p></td></tr><tr><td style="vertical-align:top"><p>Ejaculation disorders*</p></td><td style="vertical-align:top"><p>1.8%</p></td><td style="vertical-align:top"><p>0.5%</p></td></tr><tr><td style="vertical-align:top"><p>Breast disorders<sup>+</sup></p></td><td style="vertical-align:top"><p>1.3%</p></td><td style="vertical-align:top"><p>1.3%</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Allergic reactions including rash, pruritus, urticaria, localised oedema, and angioedema</p></td><td colspan="2" style="vertical-align:top"><p><strong>Incidence estimated from post-marketing data</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Depressed mood</p></td><td colspan="2" style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue diosrders</p></td><td style="vertical-align:top"><p>Alopecia (primarily body hair loss), hypertrichosis</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Testicular pain and swelling</p></td><td colspan="2" style="vertical-align:top"><p>Not known</p></td></tr></tbody></table><p>* These sexual adverse events are associated with dutasteride treatment (including monotherapy and combination with tamsulosin). These adverse events may persist after treatment discontinuation. The role of dutasteride in this persistence is unknown.</p><p><sup>+</sup>&nbsp;includes breast tenderness and breast enlargement</p><p>&nbsp;</p><p>DUTASTERIDE IN COMBINATION WITH THE ALPHA-BLOCKER TAMSULOSIN.</p><p>Data from the 4 year CombAT Study, comparing dutasteride 0.5mg (n=1623) and tamsulosin 0.4mg (n=1611) once daily alone and in combination (n=1610) have shown that the incidence of any investigator-judged drug-related adverse event during the first, second, third and fourth years of treatment respectively was 22%, 6%, 4% and 2% for dutasteride/tamsulosin combination therapy, 15%, 6%, 3% and 2% for dutasteride monotherapy and 13%, 5%, 2% and 2% for tamsulosin monotherapy. The higher incidence of adverse events in the combination therapy group in the first year of treatment was due to a higher incidence of reproductive disorders, specifically ejaculation disorders, observed in this group.</p><p>The following investigator-judged drug-related adverse events have been reported with an incidence of greater than or equal to 1% during the first year of treatment in the CombAT Study; the incidence of these events during the four years of treatment is shown in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="5"><p><strong>System Organ Class</strong></p></td><td rowspan="2"><p>Adverse Reaction</p></td><td colspan="4"><p>Incidence during treatment period</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Year 1</p></td><td><p>Year 2</p></td><td><p>Year 3</p></td><td><p>Year 4</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Combination<sup>a</sup>&nbsp;(n)</p></td><td><p>(n=1610)</p></td><td><p>(n=1428)</p></td><td><p>(n=1283)</p></td><td><p>(n=1200)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Dutasteride</p></td><td><p>(n=1623)</p></td><td><p>(n=1464)</p></td><td><p>(n=1325)</p></td><td><p>(n=1200)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Tamsulosin</p></td><td><p>(n=1611)</p></td><td><p>(n=1468)</p></td><td><p>(n=1281)</p></td><td><p>(n=1112)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td rowspan="4"><p>Nervous system disorders</p></td><td><p>Dizziness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Combination<sup>a</sup></p></td><td><p>1.4%</p></td><td><p>0.1%</p></td><td><p>&lt;0.1%</p></td><td><p>0.2%</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Dutasteride</p></td><td><p>0.7%</p></td><td><p>0.1%</p></td><td><p>&lt;0.1%</p></td><td><p>&lt;0.1%</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Tamsulosin</p></td><td><p>1.3%</p></td><td><p>0.4%</p></td><td><p>&lt;0.1%</p></td><td><p>0%</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td rowspan="4"><p>Cardiac disorders</p></td><td><p>Cardiac failure (composite term<sup>b</sup>)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Combination<sup>a</sup></p></td><td><p>0.2%</p></td><td><p>0.4%</p></td><td><p>0.2%</p></td><td><p>0.2%</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Dutasteride</p></td><td><p>&lt;0.1%</p></td><td><p>0.1%</p></td><td><p>&lt;0.1%</p></td><td><p>0%</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Tamsulosin</p></td><td><p>0.1%</p></td><td><p>&lt;0.1%</p></td><td><p>0.4%</p></td><td><p>0.2%</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td rowspan="16" style="vertical-align:top"><p>Reproductive system and breast disorders, Psychiatric disorders, Investigations</p></td><td><p>Impotence&nbsp;<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Combination<sup>a</sup></p></td><td><p>6.3%</p></td><td><p>1.8%</p></td><td><p>0.9%</p></td><td><p>0.4%</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Dutasteride</p></td><td><p>5.1%</p></td><td><p>1.6%</p></td><td><p>0.6%</p></td><td><p>0.3%</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Tamsulosin</p></td><td><p>3.3%</p></td><td><p>1.0%</p></td><td><p>0.6%</p></td><td><p>1.1%</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="7"><p>Altered (decreased) libido&nbsp;<sup>c</sup></p></td></tr><tr><td><p>Combination<sup>a</sup></p></td><td><p>5.3%</p></td><td><p>0.8%</p></td><td><p>0.2%</p></td><td><p>0%</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Dutasteride</p></td><td><p>3.8%</p></td><td><p>1.0%</p></td><td><p>0.2%</p></td><td><p>0%</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Tamsulosin</p></td><td><p>2.5%</p></td><td><p>0.7%</p></td><td><p>0.2%</p></td><td><p>&lt;0.1%</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="7"><p>Ejaculation disorders&nbsp;<sup>c</sup></p></td></tr><tr><td><p>Combination<sup>a</sup></p></td><td><p>9.0%</p></td><td><p>1.0%</p></td><td><p>0.5%</p></td><td><p>&lt;0.1%</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Dutasteride</p></td><td><p>1.5%</p></td><td><p>0.5%</p></td><td><p>0.2%</p></td><td><p>0.3%</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Tamsulosin</p></td><td><p>2.7%</p></td><td><p>0.5%</p></td><td><p>0.2%</p></td><td><p>0.3%</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="7"><p>Breast disorders<sup>d</sup></p></td></tr><tr><td><p>Combination<sup>a</sup></p></td><td><p>2.1%</p></td><td><p>0.8%</p></td><td><p>0.9%</p></td><td><p>0.6%</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Dutasteride</p></td><td><p>1.7%</p></td><td><p>1.2%</p></td><td><p>0.5%</p></td><td><p>0.7%</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Tamsulosin</p></td><td><p>0.8%</p></td><td><p>0.4%</p></td><td><p>0.2%</p></td><td><p>0%</p></td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><sup>a</sup>&nbsp;Combination = dutasteride 0.5 mg once daily plus tamsulosin 0.4 mg once daily.</p><p><sup>b</sup>&nbsp;Cardiac failure composite term comprised of Cardiac failure congestive, cardiac failure, left ventricular failure, cardiac failure acute, cardiogenic shock, left ventricular failure acute, right ventricular failure, right ventricular failure acute, ventricular failure, cardiopulmonary failure, congestive cardiomyopathy.</p><p><sup>c</sup>These sexual adverse events are associated with dutasteride treatment (including monotherapy and combination with tamsulosin). These adverse events may persist after treatment discontinuation. The role of dutasteride in this persistence is unknown.</p><p><sup>d</sup>&nbsp;Includes breast tenderness and breast enlargement.</p><p>OTHER DATA</p><p>The REDUCE study revealed a higher incidence of Gleason 8-10 prostate cancers in dutasteride treated men compared to placebo (see section 4.4 and 5.1). Whether the effect of dutasteride to reduce prostate volume, or study related factors, impacted the results of this study has not been established.</p><p>The following has been reported in clinical trials and post-marketing use: male breast cancer (see section 4.4).</p><p>&nbsp;</p><p><strong>To report any side effect(s)</strong>:</p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">- The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In volunteer studies of dutasteride, single daily doses of dutasteride up to 40 mg/day (80 times the therapeutic dose) have been administered for 7 days without significant safety concerns. In clinical studies, doses of 5 mg daily have been administered to subjects for 6 months with no additional adverse effects to those seen at therapeutic doses of 0.5 mg. There is no specific antidote for dutasteride, therefore, in suspected overdosage symptomatic and supportive treatment should be given as appropriate.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 Pharmacodynamic properties</strong></p><p>Pharmacotherapeutic group: testosterone 5 alpha-reductase inhibitors</p><p>ATC code: G04C B02</p><p>Dutasteride reduces circulating levels of dihydrotestosterone (DHT) by inhibiting both type 1 and type 2, 5&alpha; -reductase isoenzymes which are responsible for the conversion of testosterone to DHT.</p><p>DUTASTERIDE CAPSULES AS MONOTHERAPY</p><p><em>Effects on DHT/Testosterone:</em></p><p>Effect of daily doses of Dutasteride on the reduction on DHT is dose dependent and is observed within 1-2 weeks (85% and 90% reduction, respectively).</p><p>In patients with BPH treated with dutasteride 0.5 mg/day, the median decrease in serum DHT was 94% at 1 year and 93% at 2 years and the median increase in serum testosterone was 19% at both 1 and 2 years.</p><p><em>Effect on Prostate Volume:</em></p><p>Significant reductions in prostate volume have been detected as early as one month after initiation of treatment and reductions continued through Month 24 (p&lt;0.001). Dutasteride led to a mean reduction of total prostate volume of 23.6% (from 54.9ml at baseline to 42.1ml) at Month 12 compared with a mean reduction of 0.5% (from 54.0ml to 53.7ml) in the placebo group. Significant (p&lt;0.001) reductions also occurred in prostate transitional zone volume as early as one month continuing through Month 24, with a mean reduction in prostate transitional zone volume of 17.8% (from 26.8ml at baseline to 21.4ml) in the Dutasteride group compared to a mean increase of 7.9% (from 26.8ml to 27.5ml) in the placebo group at Month 12. The reduction of the prostate volume seen during the first 2 years of double-blind treatment was maintained during an additional 2 years of open-label extension studies. Reduction of the size of the prostate leads to improvement of symptoms and a decreased risk for AUR and BPH-related surgery.</p><p><em><u>Clinical efficacy and safety</u></em></p><p>Dutasteride 0.5 mg/day or placebo was evaluated in 4325 male subjects with moderate to severe symptoms of BPH who had prostates &ge;30ml and a PSA value within the range 1.5 -10 ng/mL in three primary efficacy 2-year multicenter, multinational, placebo-controlled, double-blind studies. The studies then continued with an open-label extension to 4 years with all patients remaining in the study receiving dutasteride at the same 0.5 mg dose. 37% of initially placebo-randomized patients and 40% of dutasteride-randomized patients remained in the study at 4 years. The majority (71%) of the 2,340 subjects in the open-label extensions completed the 2 additional years of open-label treatment.</p><p>The most important clinical efficacy parameters were American Urological Association Symptom Index (AUA-SI), maximum urinary flow (Qmax) and the incidence of acute urinary retention and BPH-related surgery.</p><p>AUA-SI is a seven-item questionnaire about BPH-related symptoms with a maximum score of 35. At baseline the average score was approx. 17. After six months, one and two years treatment the placebo group had an average improvement of 2.5, 2.5 and 2.3 points respectively while the Dutasteride group improved 3.2, 3.8 and 4.5 points respectively. The differences between the groups were statistically significant. The improvement in AUA-SI seen during the first 2 years of double-blind treatment was maintained during an additional 2 years of open-label extension studies.</p><p><em>Qmax (maximum urine flow):</em></p><p>Mean baseline Qmax for the studies was approx 10 ml/sec (normal Qmax &ge;15 ml/sec). After one and two years treatment the flow in the placebo group had improved by 0.8 and 0.9 ml/sec respectively and 1.7 and 2.0 ml/sec respectively in the Dutasteride group. The difference between the groups was statistically significant from Month 1 to Month 24. The increase in maximum urinary flow rate seen during the first 2 years of double-blind treatment was maintained during an additional 2 years of open-label extension studies.</p><p><em>Acute Urinary Retention and Surgical Intervention</em></p><p>After two years of treatment, the incidence of AUR was 4.2% in the placebo group against 1.8% in the Dutasteride group (57% risk reduction). This difference is statistically significant and means that 42 patients (95% CI 30-73) need to be treated for two years to avoid one case of AUR.</p><p>The incidence of BPH-related surgery after two years was 4.1% in the placebo group and 2.2% in the Dutasteride group (48% risk reduction). This difference is statistically significant and means that 51 patients (95% CI 33-109) need to be treated for two years to avoid one surgical intervention.</p><p><em>Hair distribution</em></p><p>The effect of dutasteride on hair distribution was not formally studied during the phase III programme, however, 5 alpha-reductase inhibitors could reduce hair loss and may induce hair growth in subjects with male pattern hair loss (male androgenetic alopecia).</p><p><em>Thyroid function</em></p><p>Thyroid function was evaluated in a one year study in healthy men. Free thyroxine levels were stable on dutasteride treatment but TSH levels were mildly increased (by 0.4 MCIU/mL) compared to placebo at the end of one year&#39;s treatment. However, as TSH levels were variable, median TSH ranges (1.4 -1.9 MCIU/mL ) remained within normal limits (0.5 - 5/6 MCIU/mL), free thyroxine levels were stable within the normal range and similar for both placebo and dutasteride treatment, the changes in TSH were not considered clinically significant. In all the clinical studies, there has been no evidence that dutasteride adversely affects thyroid function.</p><p><em>Breast neoplasia</em></p><p>In the 2 year clinical trials, providing 3374 patient years of exposure to dutasteride, and at the time of registration in the 2 year open label extension, there were 2 cases of male breast cancer reported in dutasteride-treated patients and 1 case in a patient who received placebo. In the 4 year CombAT and REDUCE clinical trials providing 17489 patient years exposure to dutasteride and 5027 patient years exposure to dutasteride and tamsulosin combination there were no additional cases in any of the treatment groups.</p><p>Two case control, epidemiological studies, one conducted in a US (n=339 breast cancer cases and n=6,780 controls) and the other in a UK (n=398 breast cancer cases and n=3,930 controls) healthcare database, showed no increase in the risk of developing male breast cancer with the use of 5-alpha reductase inhibitors (see section 4.4). Results from the first study did not identify a positive association for male breast cancer (relative risk for &ge; 1-year of use before breast cancer diagnosis compared with &lt; 1-year of use: 0.70: 95% CI 0.34, 1.45). In the second study, the estimated odds ratio for breast cancer associated with the use of 5-alpha reductase inhibitors compared with non-use was 1.08: 95% CI 0.62, 1.87).</p><p>A causal relationship between the occurrence of male breast cancer and long term use of dutasteride has not been established.</p><p><em>Effects on male fertility</em></p><p>The effects of dutasteride 0.5 mg/day on semen characteristics were evaluated in healthy volunteers aged 18 to 52 (n=27 dutasteride, n=23 placebo) throughout 52 weeks of treatment and 24 weeks of post-treatment follow-up. At 52 weeks, the mean percent reduction from baseline in total sperm count, semen volume and sperm motility were 23%, 26% and 18%, respectively, in the dutasteride group when adjusted for changes from baseline in the placebo group. Sperm concentration and sperm morphology were unaffected. After 24 weeks of follow-up, the mean percent change in total sperm count in the dutasteride group remained 23% lower than baseline. While mean values for all parameters at all time points remained within the normal ranges and did not meet the predefined criteria for a clinically significant change (30%), two subjects in the dutasteride group had decreases in sperm count of greater than 90% from baseline at 52 weeks, with partial recovery at the 24 week follow-up. The possibility of reduced male fertility cannot be excluded.</p><p>DUTASTERIDE IN COMBINATION WITH THE ALPHA-BLOCKER TAMSULOSIN</p><p>Dutasteride 0.5 mg/day (n = 1,623), tamsulosin 0.4 mg/day (n = 1,611) or the combination of Dutasteride 0.5 mg plus tamsulosin 0.4 mg (n = 1,610) were evaluated in male subjects with moderate to severe symptoms of BPH who had prostates &ge;30 ml and a PSA value within the range 1.5 - 10 ng/mL in a multicentre, multinational, randomized double-blind, parallel group study (the CombAT study). Approximately 53% of subjects had previous exposure to 5-alpha reductase inhibitor or alpha-blocker treatment. The primary efficacy endpoint during the first 2 years of treatment was change in International Prostate Symptom Score (IPSS), an 8-item instrument based on AUA-SI with an additional question on quality of life. Secondary efficacy endpoints at 2 years included maximum urine flow rate (Qmax) and prostate volume.</p><p>The combination achieved significance for IPSS from Month 3 compared to Dutasteride and from Month 9 compared to tamsulosin. For Qmax combination achieved significance from Month 6 compared to both Dutasteride and tamsulosin.</p><p>The primary efficacy endpoint at 4 years of treatment was time to first event of AUR or BPH-related surgery. After 4 years of treatment, combination therapy statistically significantly reduced the risk of AUR or BPH-related surgery (65.8% reduction in risk p&lt;0.001 [95% CI 54.7% to 74.1%]) compared to tamsulosin monotherapy. The incidence of AUR or BPH-related surgery by Year 4 was 4.2% for combination therapy and 11.9% for tamsulosin (p&lt;0.001). Compared to Dutasteride monotherapy, combination therapy reduced the risk of AUR or BPH-related surgery by 19.6% (p=0.18 [95% CI -10.9% to 41.7%]). The incidence of AUR or BPH-related surgery by Year 4 was 4.2% for combination therapy and 5.2% for Dutasteride.</p><p>Secondary efficacy endpoints after 4 years of treatment included time to clinical progression (defined as a composite of: IPSS deterioration by &ge;4 points, BPH-related events of AUR, incontinence, urinary tract infection (UTI), and renal insufficiency) change in International Prostate Symptom Score (IPSS), maximum urine flow rate (Qmax) and prostate volume. Results following 4 years of treatment are presented below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p>Parameter</p></td><td><p>Time-point</p></td><td><p>Combination</p></td><td><p>Dutasteride</p></td><td><p>Tamsulosin</p></td></tr><tr><td><p>AUR or BPH related surgery (%)</p></td><td><p>Incidence at Month 48</p></td><td><p>4.2</p></td><td><p>5.2</p></td><td><p>11.9a</p></td></tr><tr><td><p>Clinical progression* (%)</p></td><td><p>Month 48</p></td><td><p>12.6</p></td><td><p>17.8b</p></td><td><p>21.5a</p></td></tr><tr><td><p>IPSS (units)</p></td><td style="vertical-align:top"><p>[Baseline]</p><p>Month 48 (Change from Baseline)</p></td><td><p>[16.6]</p><p>-6.3</p></td><td><p>[16.4]</p><p>-5.3b</p></td><td><p>[16.4]</p><p>-3.8a</p></td></tr><tr><td><p>Qmax (mL/sec)</p></td><td style="vertical-align:top"><p>[Baseline]</p><p>Month 48 (Change from Baseline)</p></td><td><p>[10.9]</p><p>2.4</p></td><td><p>[10.6]</p><p>2.0</p></td><td><p>[10.7]</p><p>0.7a</p></td></tr><tr><td><p>Prostate Volume (ml)</p></td><td style="vertical-align:top"><p>[Baseline]</p><p>Month 48 (% Change from Baseline)</p></td><td><p>[54.7]</p><p>-27.3</p></td><td><p>[54.6]</p><p>-28.0</p></td><td><p>[55.8]</p><p>+4.6a</p></td></tr><tr><td><p>Prostate Transition Zone Volume (ml)#</p></td><td style="vertical-align:top"><p>[Baseline]</p><p>Month 48 (% Change from Baseline)</p></td><td><p>[27.7]</p><p>-17.9</p></td><td><p>[30.3]</p><p>-26.5</p></td><td><p>[30.5]</p><p>18.2a</p></td></tr><tr><td><p>BPH Impact Index (BII) (units)</p></td><td style="vertical-align:top"><p>[Baseline]</p><p>Month 48 (Change from Baseline)</p></td><td><p>[5.3]</p><p>-2.2</p></td><td><p>[5.3]</p><p>-1.8b</p></td><td><p>[5.3]</p><p>-1.2a</p></td></tr><tr><td style="vertical-align:top"><p>IPSS Question 8 (BPH-related Health Status) (units)</p></td><td><p>[Baseline]</p><p>Month 48 (Change from Baseline)</p></td><td><p>[3.6]</p><p>-1.5</p></td><td><p>[3.6]</p><p>-1.3b</p></td><td><p>[3.6]</p><p>-1.1a</p></td></tr></tbody></table><p>Baseline values are mean values and changes from baseline are adjusted mean changes.</p><p>* Clinical progression was defined as a composite of: IPSS deterioration by &ge;4 points, BPH-related events of AUR, incontinence, UTI, and renal insufficiency.</p><p># Measured at selected sites (13% of randomized patients)</p><p>a. Combination achieved significance (p&lt;0.001) vs. tamsulosin at Month 48</p><p>b. Combination achieved significance (p&lt;0.001) vs. Dutasteride at Month 48</p><p>CARDIAC ADVERSE EVENTS<em>:</em></p><p>In a 4 year BPH study of dutasteride in combination with tamsulosin in 4844 men (the CombAT study) the incidence of the composite term cardiac failure in the combination group (14/1610, 0.9%) was higher than in either monotherapy group: Dutasteride , (4/1623, 0.2%) and tamsulosin, (10/1611, 0.6%).</p><p>In a separate 4-year study in 8231 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10.0 ng/mL in the case of men 50 to 60 years of age, or 3 ng/mL and 10.0 ng/mL in the case of men older than 60 years of age) (the REDUCE study), there was a higher incidence of the composite term cardiac failure in subjects taking Dutasteride 0.5 mg once daily (30/4105, 0.7%) compared to subjects taking placebo (16/4126, 0.4%). A post-hoc analysis of this study showed a higher incidence of the composite term cardiac failure in subjects taking Dutasteride and an alpha blocker concomitantly (12/1152, 1.0%), compared to subjects taking Dutasteride and no alpha blocker (18/2953, 0.6%), placebo and an alpha blocker (1/1399, &lt;0.1%), or placebo and no alpha blocker (15/2727, 0.6%) (see section 4.4).</p><p>In a meta-analysis of 12-randomised, placebo- or comparator-controlled clinical studies (n=18,802) that evaluated the risks of developing cardiovascular adverse events from the use of dutasteride (by comparison with controls), no consistent statistically significant increase in the risk of heart failure (RR 1.05; 95% CI 0.71, 1.57), acute myocardial infarction (RR 1.00; 95% CI 0.77, 1.30) or stroke (RR 1.20; 95% CI 0.88, 1.64) were found.</p><p>&nbsp;</p><p><strong>Prostate cancer and high grade tumours</strong></p><p>In a 4-year comparison of placebo and Dutasteride in 8231 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10.0 ng/mL in the case of men 50 to 60 years of age, or 3 ng/mL and 10.0 ng/mL in the case of men older than 60 years of age) (the REDUCE study) 6,706 subjects had prostate needle biopsy (primarily protocol mandated) data available for analysis to determine Gleason Scores. There were 1517 subjects diagnosed with prostate cancer in the study. The majority of biopsy-detectable prostate cancers in both treatment groups were diagnosed as low grade (Gleason 5-6, 70%).</p><p>There was a higher incidence of Gleason 8-10 prostate cancers in the Dutasteride group (n=29, 0.9%) compared to the placebo group (n=19, 0.6%) (p=0.15). In Years 1-2, the number of subjects with Gleason 8-10 cancers was similar in the Dutasteride group (n=17, 0.5%) and the placebo group (n=18, 0.5%). In Years 3-4, more Gleason 8-10 cancers were diagnosed in the Dutasteride group (n=12, 0.5%) compared with the placebo group (n=1, &lt;0.1%) (p=0.0035). There are no data available on the effect of Dutasteride beyond 4 years in men at risk of prostate cancer. The percentage of subjects diagnosed with Gleason 8-10 cancers was consistent across study time periods (Years 1-2 and Years 3-4) in the Dutasteride group (0.5% in each time period), while in the placebo group, the percentage of subjects diagnosed with Gleason 8-10 cancers was lower during Years 3-4 than in Years 1-2 (&lt;0.1% versus 0.5%, respectively) (see section 4.4). There was no difference in the incidence of Gleason 7-10 cancers (p=0.81).</p><p>The additional 2-year follow-up study of the REDUCE trial did not identify any new cases of Gleason 8&ndash;10 prostate cancers.</p><p>In a 4 year BPH study (CombAT) where there were no protocol-mandated biopsies and all diagnoses of prostate cancer were based on for-cause biopsies, the rates of Gleason 8-10 cancer were (n=8, 0.5%) for Dutasteride, (n=11, 0.7%) for tamsulosin and (n=5, 0.3%) for combination therapy.</p><p>Four different epidemiological, population-based studies (two of which were based on a total population of 174,895, one on a population of 13,892, and one on a population of 38,058) showed that the use of 5-alpha reductase inhibitors is not associated with the occurrence of high grade prostate cancer, nor with prostate cancer, or overall mortality.</p><p>The relationship between Dutasteride and high grade prostate cancer is not clear.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption</em></p><p>Following oral administration of a single 0.5 mg dutasteride dose, the time to peak serum concentrations of dutasteride is 1 to 3 hours. The absolute bioavailability is approximately 60%. The bioavailability of dutasteride is not affected by food.</p><p><em>Distribution</em></p><p>Dutasteride has a large volume of distribution (300 to 500 L) and is highly bound to plasma proteins (&gt;99.5%). Following daily dosing, dutasteride serum concentrations achieve 65% of steady state concentration after 1 month and approximately 90% after 3 months.</p><p>Steady state serum concentrations (Css) of approximately 40 ng/mL are achieved after 6 months of dosing 0.5 mg once a day. Dutasteride partitioning from serum into semen averaged 11.5%.</p><p><em>Biotransformation</em></p><p>Dutasteride is extensively metabolized in vivo.&nbsp;<em>In vitro</em>, dutasteride is metabolized by the cytochrome P450 3A4 and 3A5 to three monohydroxylated metabolites and one dihydroxylated metabolite.</p><p>Following oral dosing of dutasteride 0.5 mg/day to steady state, 1.0% to 15.4% (mean of 5.4%) of the administered dose is excreted as unchanged dutasteride in the faeces. The remainder is excreted in the faeces as 4 major metabolites comprising 39%, 21%, 7%, and 7% each of drug-related material and 6 minor metabolites (less than 5% each). Only trace amounts of unchanged dutasteride (less than 0.1% of the dose) are detected in human urine.</p><p><em>Elimination</em></p><p>The elimination of dutasteride is dose dependent and the process appears to be described by two elimination pathways in parallel, one that is saturable at clinically relevant concentrations and one that is non saturable.</p><p>At low serum concentrations (less than 3 ng/mL), dutasteride is cleared rapidly by both the concentration dependent and concentration independent elimination pathways. Single doses of 5 mg or less showed evidence of rapid clearance and a short half-life of 3 to 9 days.</p><p>At therapeutic concentrations, following repeat dosing of 0.5 mg/day, the slower, linear elimination pathway is dominating and the half-life is approx. 3-5 weeks.</p><p><em>Elderly</em></p><p>Dutasteride pharmacokinetics were evaluated in 36 healthy male subjects between the ages of 24 and 87 years following administration of a single 5 mg dose of dutasteride. No significant influence of age was seen on the exposure of dutasteride but the half-life was shorter in men under 50 years of age. Half-life was not statistically different when comparing the 50-69 year old group to the greater than 70 years old.</p><p><u>Renal impairment</u></p><p>The effect of renal impairment on dutasteride pharmacokinetics has not been studied. However, less than 0.1% of a steady-state 0.5 mg dose of dutasteride is recovered in human urine, so no clinically significant increase of the dutasteride plasma concentrations is anticipated for patients with renal impairment (see section 4.2).</p><p><u>Hepatic impairment</u></p><p>The effect on the pharmacokinetics of dutasteride in hepatic impairment has not been studied (see section 4.3). Because dutasteride is eliminated mainly through metabolism the plasma levels of dutasteride are expected to be elevated in these patients and the half-life of dutasteride be prolonged (see section 4.2 and section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Current studies of general toxicity, genotoxicity and carcinogenicity did not show any particular risk to humans.</p><p>Reproduction toxicity studies in male rats have shown a decreased weight of the prostate and seminal vesicles, decreased secretion from accessory genital glands and a reduction in fertility indices (caused by the pharmacological effect of dutasteride). The clinical relevance of these findings is unknown.</p><p>As with other 5 alpha-reductase inhibitors, feminisation of male foetuses in rats and rabbits has been noted when dutasteride was administered during gestation. Dutasteride has been found in blood from female rats after mating with dutasteride treated males. When dutasteride was administered during gestation to primates, no feminisation of male foetuses was seen at blood exposures sufficiently in excess of those likely to occur via human semen. It is unlikely that a male foetus will be adversely affected following seminal transfer of dutasteride.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glycerol Monocrylocaprate</p><p>Butylated Hydroxy Toluene</p><p>Gelatin</p><p>Glycerin</p><p>Titanium dioxide</p><p>Ferric oxide yellow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original container to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium- PVC/PVDC blister pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oct-19 
SPC-045-00

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>